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Introduction {#Sec1}
============

Several longitudinal prospective studies have followed children at increased risk for type 1 diabetes. A secondary objective in some studies has been to investigate whether study participation influenced clinical status at, and after, diagnosis. Children enrolled in follow-up studies have been reported to have a lower frequency of diabetic ketoacidosis (DKA) and other metabolic abnormalities at diagnosis \[[@CR1], [@CR2]\] as well as a milder clinical course after diagnosis \[[@CR3]\]. However, the long-term effects of these findings are not clear.

It has been proposed that early diagnosis and initiation of insulin treatment could have a beneficial effect on preservation of beta cell mass \[[@CR4]\]. Recent data contradict this and report a similar pattern of C-peptide decline even if diabetes is diagnosed very early \[[@CR5]\]. Despite this, children who have been enrolled in prospective follow-up tend to have improved glycaemic control compared with the general population \[[@CR3]\].

The Diabetes Prediction in Skåne (DiPiS) study is a prospective, longitudinal study of children at increased risk for type 1 diabetes. We have previously described improved metabolic status at diagnosis and the 2 years after diagnosis for study participants \[[@CR6]\]. The aim of this study was to examine whether the positive effect on metabolic control remains after the cohort has reached 5 years after diabetes diagnosis.

Methods {#Sec2}
=======

The DiPiS study is a prospective, longitudinal study on diabetes prediction in the southern part of Sweden where 38,683 children were screened for type 1 diabetes risk between September 2000 and August 2004. When the child was 2 months of age, parents were invited to participate in the study and asked to answer a questionnaire regarding pregnancy, perinatal and socioeconomic factors. When the child was 2 years old, parents were asked if they would like to be informed of the type 1 diabetes risk of their child. If they agreed, risk information was then sent to parents.

Participants were screened yearly for islet autoantibodies and were asked to complete a questionnaire. Children who developed two or more islet autoantibodies were offered follow-up every 3 months with autoantibody sampling, HbA~1c~, random plasma glucose and yearly oral glucose tolerance tests \[[@CR6]\]. Children in follow-up were informed of risk after each blood sampling. The regional ethics review board in Lund, Sweden, approved the study. All parents gave informed consent to participate.

Study group definition {#FPar1}
----------------------

For this study, the 143 children born during 2000--2004 in the Skåne region and diagnosed with type 1 diabetes before 31 July 2013 were selected, 14 of whom were excluded because they were diagnosed before 2 years of age. This study compares the group of 51 children who had some degree of follow-up before diabetes diagnosis and who had received information on type 1 diabetes risk (follow-up group \[FU\]) with the 78 children who had declined to participate and had not received any information on type 1 diabetes risk (no follow-up group \[NFU\]) (electronic supplementary material \[ESM\] Fig. [1](#MOESM1){ref-type="media"}). Baseline demographics and status at diagnosis have been described previously \[[@CR6]\].

Baseline data {#FPar2}
-------------

Data regarding the parents' country of birth, maternal smoking, maternal alcohol consumption during pregnancy, marital status and maternal age were collected from the study questionnaire completed when the child was 2 months of age. First-degree relative (FDR) status was retrieved from patient records and the 2 month questionnaire. Unfortunately, the data on FDRs did not enable us to distinguish type 1 diabetes from other diabetes treated with insulin; hence, denoted insulin-dependent diabetes (IDDM). DKA was defined as blood pH \<7.3. HLA DQ genotyping and risk stratification were performed as described previously \[[@CR6]\].

Follow-up data acquisition {#FPar3}
--------------------------

Diagnosis of diabetes was obtained by paediatrician report and from the diabetes incidence register of the Better Diabetes Diagnosis study (BDD) \[[@CR7]\]. Following diagnosis, children received care from one of the region's six paediatric diabetes centres. No study visits were performed after diagnosis. Follow-up data were recorded at 3, 6, 12 and 24 months (±1 month), 3 and 4 years (±3 months), and 5 years (±6 months) post-diagnosis. HbA~1c~ was analysed using a DCA Vantage+ (Bayer, Tarrytown, NY, USA) or Alere Afinion (Alere, Waltham, MA, USA) analyser, both of which were calibrated by the same central laboratory. C-peptide measurements were not determined for participants after diagnosis. Insulin dose--adjusted HbA~1c~ (IDAA~1c~) was defined as HbA~1c~ (in %) + \[4 × insulin dose (in U kg^−1^ day^−1^)\], where partial remission was defined as an IDAA~1c~ of ≤9 \[[@CR8]\].

Statistical analysis {#FPar4}
--------------------

Differences between continuous variables were calculated using the Mann--Whitney *U* test and between categorical variables using Pearson's χ^2^ and Fisher's exact test. A *p* value \<0.05 was considered significant. Data were analysed using R version 3.44 (<https://www.r-project.org>).

Results {#Sec3}
=======

Baseline demographics {#FPar5}
---------------------

A total of 129 children diagnosed with diabetes were included in the analysis, 51 in the FU group and 78 in the NFU group. The mean age at diagnosis was 6.8 ± 2.9 (mean ± SD) years in the FU group and 6.5 ± 2.6 years in the NFU group (ESM Table [1](#MOESM1){ref-type="media"}). The FU group had a higher frequency of FDRs with IDDM compared with the NFU group (*n* = 14 \[28%\] vs *n* = 4 \[5.6%\], respectively, *p* = 0.001). The FU group had a higher proportion of mothers born in Sweden (*n* = 50 \[100%\]) compared with the NFU group (*n* = 39 \[88.6%\], *p* = 0.02). Hereditary and sociodemographic factors are presented in ESM Table [1](#MOESM1){ref-type="media"}.

Insulin use and partial remission {#FPar6}
---------------------------------

No significant differences in total daily insulin dose were observed between the two groups during follow-up (all *p* \> 0.05) (Table [1](#Tab1){ref-type="table"}). The use of insulin pumps (continuous subcutaneous insulin infusion; CSII) during follow-up and the proportion of children using CSII did not differ between the two groups at any time point (ESM Table [1](#MOESM1){ref-type="media"}). The cumulative number of years on CSII also did not differ (*p* = 0.73) (ESM Table [1](#MOESM1){ref-type="media"}). Frequency of partial remission, defined as IDAA~1c~ ≤9, was the same in both groups at all time-points except at 3 months after diagnosis (ESM Table [1](#MOESM1){ref-type="media"}).Table 1HbA~1c~ and total daily insulin dose during the first 5 years after diabetes diagnosisVariableFU groupNFU group*pn*Median (IQR)Median (IQR)*n*Median (IQR)Median (IQR)HbA~1c~IFCC (mmol/mol)NGSP (%)IFCC (mmol/mol)NGSP (%) Diagnosis5177 (27)9.2 (4.6)7786 (23.5)10.0 (4.3)0.006 3 months4849 (11.5)6.6 (3.2)7550 (14)6.7 (3.4)0.261 6 months5150 (15)6.7 (3.5)7653.5 (17)7.0 (3.7)0.479 1 year5153 (9)7.0 (3.0)7856 (15)7.3 (3.5)0.012 2 years5153(12)7.0 (3.2)7758 (15)7.5 (3.5)0.002 3 years5156 (9.8)7.3 (3.0)7360 (10.5)7.6 (3.1)0.014 4 years5057 (11)7.4 (3.2)7561 (8.5)7.7 (2.9)0.001 5 years4655.5 (12)7.2 (3.2)7460.5 (12)7.7 (3.2)0.012TDD (U kg^−1^ day^−1^) 3 months500.47 (0.287)--780.52 (0.265)--0.056 6 months500.60 (0.35)--770.62 (0.33)--0.435 1 year500.74 (0.36)--770.75 (0.31)--0.733 2 years500.80 (0.41)--760.84 (0.35)--0.655 3 years430.83 (0.39)--640.83 (0.38)--0.384 4 years440.92 (0.41)--670.93 (0.41)--0.842 5 years370.85 (0.40)--630.92 (0.55)--0.157Differences between groups were calculated using the Mann--Whitney *U* testTDD, total daily insulin dose

HbA~1c~ after diagnosis {#FPar7}
-----------------------

Compared with the NFU group, HbA~1c~ levels at diabetes diagnosis were significantly lower in the FU group (*p* = 0.006), as well as at 1 year (*p* = 0.012), 2 years (*p* = 0.002), 3 years (*p* = 0.014), 4 years (*p* = 0.001), and 5 years (*p* = 0.012) after the diagnosis (Table [1](#Tab1){ref-type="table"}). The median HbA~1c~ during the total 5 year follow-up was lower for the FU group (53.3 mmol/mol, interquartile range \[IQR\] 7.5) than for the NFU group (57.7 mmol/mol, \[IQR 8.6\]; *p* = 0.001). No differences were observed at 3 and 6 months after diagnosis (*p* = 0.26 and *p* = 0.48, respectively) (Fig. [1](#Fig1){ref-type="fig"}, Table [1](#Tab1){ref-type="table"}). A separate analysis excluding all participants with DKA at diagnosis, was concordant with the full cohort analysis (ESM Table [2](#MOESM1){ref-type="media"}). In addition, an analysis excluding all participants with an FDR with IDDM was also consistent with the total cohort analysis (ESM Table [3](#MOESM1){ref-type="media"}).Fig. 1HbA~1c~ levels at diagnosis and the 5 years following diagnosis. Solid line, FU group; dotted line, NFU group

Discussion {#Sec4}
==========

In this study, we found that children previously enrolled in longitudinal follow-up have better metabolic control at diagnosis of diabetes, and that this positive effect on HbA~1c~ in this cohort remains for at least 5 years. In this study we compared children from the general population with a group previously enrolled in a prospective study on diabetes prediction; the clinical follow-up after diagnosis did not differ between the groups.

Several longitudinal studies have previously reported that children, followed for their increased type 1 diabetes risk, are diagnosed at an early stage of the disease with less morbidity and better initial glycaemic control \[[@CR1], [@CR3]\]. Additionally, The Environmental Determinants of Diabetes in the Young (TEDDY) study has reported both lower frequency of DKA and symptoms at diagnosis, as well as higher levels of C-peptide, for children previously enrolled in their study \[[@CR9]\]. Recent data also show that families of children who were enrolled in the TEDDY study have better diabetes-related quality of life and lower parental parenting stress after diabetes diagnosis compared with children from the general population \[[@CR10]\]. That an early diagnosis would lead to higher levels of remaining C-peptide has been proposed as an important factor. However, it is surprising that this effect would last as long as 5 years \[[@CR5]\]. The FU group had a significantly lower frequency of DKA at diagnosis than the NFU group, and this has been attributed to higher levels of residual C-peptide \[[@CR11]\]. In this cohort, no differences in remission were detected when analysing IDAA~1c~ or excluding participants with DKA at diagnosis.

Weaknesses of this analysis include measurement of a limited number of variables during clinical care, including a lack of C-peptide and of updated psychosocial and psychological data. Another limitation is that two different analysers (the DCA Vantage+ and Alere Infineon) were used to determine HbA~1c~ measurements, although they were calibrated by the same central laboratory. Strengths of the current study include the wide-scale screening of the DiPiS study, follow-up after diagnosis with similar diabetes care, data retrieval from patient records and incidence data from the BDD study with excellent coverage.

In conclusion, our study provides evidence that children enrolled in follow-up in the DiPiS study before diabetes diagnosis have better glycaemic control after diagnosis than children who did not participate in the study, and that this effect remains for at least 5 years after diagnosis. This improved glycaemic control could improve long-term outcome and reduce the risk of complications.
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BDD

:   Better diabetes diagnosis study

CSII

:   Continuous subcutaneous insulin infusion

DiPiS

:   Diabetes Prediction in Skåne

DKA

:   Diabetes ketoacidosis

FDR

:   First-degree relative

FU

:   Follow-up group

IDAA~1c~

:   Insulin dose-adjusted HbA~1c~

IDDM

:   Insulin-dependent diabetes mellitus

NFU

:   No follow-up group

TEDDY

:   The Environmental Determinants of Diabetes in the Young
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